Semaglutide CoA: What to Check in GLP-1 HPLC Purity

If you are sourcing semaglutide for research applications, the certificate of analysis is the first document your QA team will read — and the one most often misread. The question "semaglutide CoA what to check" has a short answer and a long answer. The short answer: purity by HPLC, method parameters, and identity confirmation. The long answer is what this article covers, drawn from our own method development work and the failure cases we have seen across supplier submissions.

Why HPLC purity alone does not tell you what you need to know

A CoA that states "purity: 99.2% by HPLC" is not a specification. It is a number without a method. Two labs can analyze the same lot and report 97.8% and 99.4% — both defensible — because the column, gradient, wavelength, and integration parameters differ. For GLP-1 peptides like semaglutide, this gap is wider than for small molecules because the molecule is large, modified, and prone to specific degradation pathways.

When we review a supplier CoA, the purity figure is the last thing we look at. We read the method first.

What a defensible semaglutide HPLC method looks like

Semaglutide is a 31-amino-acid GLP-1 analog with a C18 fatty diacid side chain and two non-natural amino acids (Aib at position 8, and a modified Lys at position 26). That structure dictates the analytical approach.

Column and mobile phase

• Column: C18, 3–5 µm, 150–250 mm. We use a 4.6 × 250 mm, 5 µm column for release testing and a 2.1 × 100 mm, 1.8 µm column for in-process checks. Shorter columns resolve faster but compress the impurity window.
• Mobile phase: Typically 0.1% TFA in water (A) and 0.1% TFA in acetonitrile (B). Some labs use formic acid for LC-MS compatibility, but TFA generally gives better peak shape for this peptide.
• Gradient: A shallow gradient (typically 25–45% B over 30–40 minutes) is required to separate the deamidated and oxidized variants from the main peak. Steep gradients collapse these into the parent peak.
• Wavelength: 214 nm for the peptide backbone. 280 nm is sometimes added for Trp-containing fragments, but 214 nm is the primary channel.

System suitability

A method without system suitability data is unverifiable. We require the CoA to show: resolution between the main peak and the nearest impurity (≥ 1.5), tailing factor (≤ 2.0), theoretical plates (≥ 5000), and RSD of replicate injections (≤ 2.0%). If these are absent, the purity number is not actionable.

Our CoA review guide covers the full document checklist, including the sections most buyers skip.

Failure cases we have seen in supplier submissions

These are not hypothetical. They are patterns from real submissions we have rejected or flagged over the past two years.

Case 1: The 99.9% that was actually 96.4%

A supplier submitted a CoA reporting 99.9% purity by HPLC. The method listed a 15-minute gradient on a 50 mm column. When we re-ran the same lot on our 250 mm method, the main peak resolved into three components: the parent peptide at 96.4%, a deamidated variant at 2.1%, and an oxidized variant at 1.2%. The supplier's method had not resolved the impurities — they co-eluted with the main peak. The supplier was not lying. Their method was simply not fit for purpose.

Case 2: The missing mass confirmation

A CoA showed 98.7% purity by HPLC but no mass spectrometry data. HPLC purity tells you how much of the UV-absorbing material is the main peak. It does not tell you the main peak is semaglutide. We require ESI-MS or MALDI-TOF confirmation with the observed mass within 0.1% of theoretical (4113.6 Da for semaglutide free base). Without this, a CoA could describe a closely related analog and still show high purity.

Case 3: The counterion that was not declared

Semaglutide is commonly supplied as the acetate salt. A CoA that reports purity by HPLC but does not declare the counterion, residual TFA, or water content is incomplete. We have seen lots where the peptide content was 78% of the stated mass because the rest was counterion and moisture. For research applications where molar concentration matters, this is a material error.

What to check on a semaglutide CoA: a working checklist

This is the sequence our QA team uses. It is not exhaustive, but it catches the failures that matter most.

• Method parameters: column dimensions, particle size, mobile phase composition, gradient profile, detection wavelength, flow rate, injection volume.
• System suitability: resolution, tailing, plates, RSD. All four, with acceptance criteria.
• Purity figure: with the integration method stated (e.g., area % at 214 nm, impurities above 0.1% threshold).
• Impurity profile: individual impurities named or characterized where possible, not just a total.
• Identity: mass spectrometry data with observed vs. theoretical mass.
• Counterion and water content: acetate content, residual TFA, Karl Fischer water.
• Residual solvents: if the synthesis route uses them, a residual solvent statement or GC data.
• Batch and lot traceability: lot number, manufacturing date, retest date, and the site of manufacture.

For a worked example of how this checklist applies to a related GLP-1 peptide, see our tirzepatide CoA walkthrough.

Method development: what we learned the hard way

Getting a semaglutide HPLC method to resolve the deamidated variant from the parent peak is not trivial. Our first method, a 20-minute gradient on a 150 mm column, gave a resolution of 1.1 — below our internal threshold of 1.5. We spent three weeks adjusting gradient slope and column temperature before we achieved baseline resolution. The final method runs 45 minutes and uses a column temperature of 40°C, which sharpens the peaks without accelerating degradation.

This matters because a supplier's method is often a compromise between resolution and throughput. If their method runs in 15 minutes, ask what they sacrificed. It is usually resolution.

Cost structure of proper testing

For context on what a rigorous CoA costs to produce: a full release panel for semaglutide — HPLC purity, ESI-MS identity, counterion, water content, and residual solvents — runs between $800 and $1,500 per lot at a contract lab, depending on turnaround and whether method development is included. A supplier charging $200 for a CoA is not running this panel. That does not automatically make the material unfit, but it does mean the documentation is thinner than it appears.

How Helix Peptide approaches GLP-1 HPLC purity

We manufacture semaglutide and related GLP-1 peptides under GMP conditions and release each lot against the checklist above. Our internal purity specification is ≥ 98.0% by our 45-minute method, with individual impurities reported above 0.1%. We provide mass confirmation, counterion data, and water content on every CoA. If a lot does not meet these criteria, it does not ship for research use.

We also publish our method parameters so buyers can compare apples to apples. If a competing CoA does not state its method, that is a data point in itself.

Conclusion: semaglutide CoA what to check, in one sentence

Check the method before the purity number, confirm identity by mass spectrometry, and verify that counterion and water content are declared — because a purity figure without method context is not a specification, and a CoA without identity confirmation is not a certificate.

If you are evaluating a semaglutide lot for research applications and want a second opinion on the CoA, our QA team can review it. Request a quote or send your CoA for review.